The Rogosin Institute Inc.

The Rogosin Institute Inc. is a nonprofit organization based in New York City that specializes in renal disease research and clinical care. As a tax-exempt corporate entity registered in SAM.gov since March 2009, the institute provides critical diagnostic and research services to the federal government through both prime contract and grant awards. The organization has established itself as a specialized partner for federal health initiatives, particularly in nephrology and kidney transplantation support, combining advanced immunogenetics testing capabilities with significant federal research initiatives aimed at advancing renal replacement therapy.

Through its federal contract awards, The Rogosin Institute has consistently provided tissue typing and immunogenetics testing services to support the Veterans Health Administration's renal transplant program. Specifically, the institute holds an Indefinite Delivery Contract valued at approximately $1.03 million with the Department of Veterans Affairs Veterans Integrated Service Network 2 (VA-VHA VISN 2), under which it has received multiple delivery orders since 2021. The most recent delivery order, awarded December 1, 2025, is valued at $209,190 and extends through May 31, 2026, while prior delivery orders have ranged from approximately $102,926 to $224,330 in value. These contracts are firm fixed-price arrangements that require the institute to perform human leukocyte antigen (HLA) typing and tissue matching services at the James J. Peters VA Medical Center in the Bronx, New York, to facilitate kidney transplants for veterans in the New York City area. All contract awards have been made without set-aside designations, indicating open competition. The institute's contract work directly supports the VA's mission to improve organ transplant outcomes for veterans through specialized diagnostic services.

Through federal grant awards, The Rogosin Institute serves as a prime grantee under the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a project grant focused on "Application of Progenitor Niche Signals to Ex Vivo Nephrogenesis," which runs through June 30, 2026. This research initiative addresses the critical shortage of available kidneys for transplant by developing techniques to generate functionally integrated kidney organoids from human induced pluripotent stem cells (iPSCs) for potential use in renal replacement therapy. The institute has also participated in multiple federal grant sub-awards from various prime grantees, including collaborative roles with Weill Medical College of Cornell University, the University of Maryland Baltimore, The Mount Desert Island Biological Laboratory, and the University of Pennsylvania. These sub-awards have involved recruitment and clinical site responsibilities for studies addressing pain management in dialysis patients, polycystic kidney disease research coordination through the PKD Research and Translation Core Centers, participation in the (RE)Building a Kidney Consortium, and pain coping skills training interventions for end-stage renal disease patients. The institute's grant portfolio demonstrates its commitment to advancing both the scientific understanding of kidney disease and the clinical management of patients with renal conditions, positioning it as an active participant in federally funded collaborative research networks focused on renal health and transplantation.